The Experts below are selected from a list of 23451 Experts worldwide ranked by ideXlab platform
Ele Ferrannini - One of the best experts on this subject based on the ideXlab platform.
-
Chemokine c x c motif ligand cxcl 10 in autoimmune diseases
Autoimmunity Reviews, 2014Co-Authors: Alessandro Antonelli, Ele Ferrannini, Silvia Martina Ferrari, Dilia Giuggioli, Clodoveo Ferri, Poupak FallahiAbstract:(C–X–C motif) ligand (CXCL)10 (CXCL10) belongs to the ELR− CXC subfamily Chemokine. CXCL10 exerts its function through binding to Chemokine (C–X–C motif) receptor 3 (CXCR3), a seven trans-membrane receptor coupled to G proteins. CXCL10 and its receptor, CXCR3, appear to contribute to the pathogenesis of many autoimmune diseases, organ specific (such as type 1 diabetes, autoimmune thyroiditis, Graves' disease and ophthalmopathy), or systemic (such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, mixed cryoglobulinemia, Sjogren syndrome, or systemic sclerosis). The secretion of CXCL10 by cluster of differentiation (CD)4 +, CD8 +, natural killer (NK) and NK-T cells is dependent on interferon (IFN)-γ, which is itself mediated by the interleukin-12 cytokine family. Under the influence of IFN-γ, CXCL10 is secreted by several cell types including endothelial cells, fibroblasts, keratinocytes, thyrocytes, preadipocytes, etc. Determination of high level of CXCL10 in peripheral fluids is therefore a marker of host immune response, especially T helper (Th)1 orientated T-cells. In tissues, recruited Th1 lymphocytes may be responsible for enhanced IFN-γ and tumor necrosis factor-α production, which in turn stimulates CXCL10 secretion from a variety of cells, therefore creating an amplification feedback loop, and perpetuating the autoimmune process. Further studies are needed to investigate interactions between Chemokines and cytokines in the pathogenesis of autoimmune diseases and to evaluate whether CXCL10 is a novel therapeutic target in various autoimmune diseases.
-
monokine induced by interferon gamma ifngamma cxcl9 and ifngamma inducible t cell alpha chemoattractant cxcl11 involvement in graves disease and ophthalmopathy modulation by peroxisome proliferator activated receptor gamma agonists
The Journal of Clinical Endocrinology and Metabolism, 2009Co-Authors: Alessandro Antonelli, Poupak Fallahi, Stefano Sellari Franceschini, Silvia Martina Ferrari, Silvia Frascerra, Eleonora Santini, Ele FerranniniAbstract:Context: CXC α-Chemokine CXCL10/IP-10 plays an important role in the initial phases of Graves’ ophthalmopathy (GO). Human thyrocytes, orbital fibroblasts, and preadipocytes are stimulated to produce CXCL10 when treated with interferon γ (IFNγ) and TNFα. Peroxisome proliferator-activated receptor-γ (PPARγ) activation plays an inhibitory role in this process. Objective: Until now, no data are present in literature about the involvement of CXCL9 and CXCL11 in Graves’ disease and GO, or of PPARγ activators’ effect on these Chemokines. Methods: It has been studied how IFNγ and TNFα stimulation and PPARγ activation affect CXCL9 and CXCL11 secretion in primary cultures of thyrocytes, orbital fibroblasts, and preadipocytes. Results: In primary cultures of thyrocytes, retrobulbar fibroblasts, and retrobulbar preadipocytes obtained from GO patients, CXCL9 and CXCL11 production was absent under basal conditions; CXCL9 and CXCL11 secretion was not induced by TNFα alone, whereas it was dose dependently stimulated trea...
-
monokine induced by interferon γ ifnγ cxcl9 and ifnγ inducible t cell α chemoattractant cxcl11 involvement in graves disease and ophthalmopathy modulation by peroxisome proliferator activated receptor γ agonists
The Journal of Clinical Endocrinology and Metabolism, 2009Co-Authors: Alessandro Antonelli, Poupak Fallahi, Stefano Sellari Franceschini, Silvia Martina Ferrari, Silvia Frascerra, Eleonora Santini, Ele FerranniniAbstract:Context: CXC α-Chemokine CXCL10/IP-10 plays an important role in the initial phases of Graves’ ophthalmopathy (GO). Human thyrocytes, orbital fibroblasts, and preadipocytes are stimulated to produce CXCL10 when treated with interferon γ (IFNγ) and TNFα. Peroxisome proliferator-activated receptor-γ (PPARγ) activation plays an inhibitory role in this process. Objective: Until now, no data are present in literature about the involvement of CXCL9 and CXCL11 in Graves’ disease and GO, or of PPARγ activators’ effect on these Chemokines. Methods: It has been studied how IFNγ and TNFα stimulation and PPARγ activation affect CXCL9 and CXCL11 secretion in primary cultures of thyrocytes, orbital fibroblasts, and preadipocytes. Results: In primary cultures of thyrocytes, retrobulbar fibroblasts, and retrobulbar preadipocytes obtained from GO patients, CXCL9 and CXCL11 production was absent under basal conditions; CXCL9 and CXCL11 secretion was not induced by TNFα alone, whereas it was dose dependently stimulated trea...
-
α Chemokine CXCL10 and β Chemokine ccl2 serum levels in patients with hepatitis c associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis
Metabolism-clinical and Experimental, 2008Co-Authors: Alessandro Antonelli, Poupak Fallahi, Silvia Martina Ferrari, Silvia Frascerra, Clodoveo Ferri, Angelo Carpi, Andrea Nicolini, Ele FerranniniAbstract:Chemokines have been identified to play an important role in endocrine autoimmune disease and hepatitis C chronic infection. To our knowledge, no study has evaluated serum levels of CXCL10 and CCL2 in patients with “mixed cryoglobulinemia and hepatitis C virus chronic infection” (MC) in the presence or absence of autoimmune thyroiditis (AT). Serum CXCL10 and CCL2 were assayed in 60 patients with MC, in 45 patients with “MC with AT” (MC + AT), and in controls (60 without [control 1] and 45 with AT [control 2]). CXCL10 was significantly higher (1) in control 2 than in control 1 (P mean + SD control 1; >167 pg/mL) was present in 7% control 1, 21% control 2, 49% MC, and 78% MC + AT (P mean + SD control 1; >730 pg/mL) was present in 2% control 1, 1% control 2, 18% MC, and 21% MC + AT (P < .0001). The study demonstrates high CXCL10 and CCL2 serum levels in patients with MC; CXCL10 in MC + AT is significantly higher than that in MC. Future studies in larger series will be needed to evaluate the potential usefulness of serum CXCL10 and CCL2 determination as a prognostic marker in the follow-up of MC patients, also in relation to the presence of AT.
-
iodine 131 given for therapeutic purposes modulates differently interferon γ inducible α Chemokine CXCL10 serum levels in patients with active graves disease or toxic nodular goiter
The Journal of Clinical Endocrinology and Metabolism, 2007Co-Authors: Alessandro Antonelli, Poupak Fallahi, Paola Romagnani, Mario Serio, Mariano Grosso, Giuseppe Boni, Silvia Martina Ferrari, Giuliano Mariani, M Rotondi, Ele FerranniniAbstract:CONTEXT: The mechanism of activation of the immune system after iodine-131 (131I) treatment of hyperthyroidism is still not fully clarified. Serum levels of CXCL10, a prototype of the CXC family of Chemokines, are increased in several endocrine autoimmune conditions, and this Chemokine plays a role at least in the initial phases of thyroid autoimmune disease and in Graves' disease (GD). OBJECTIVE, DESIGN, AND PATIENTS: The aim of the present study was to measure the serum CXCL10 levels in 20 patients with GD and 10 patients with toxic nodular goiter (TNG) before and 6 months after 131I treatment, when patients had achieved euthyroidism. Forty healthy subjects and 40 patients with autoimmune thyroiditis served as control groups. RESULTS: Before 131I, mean CXCL10 was significantly higher in patients with GD and thyroiditis than controls or those with TNG. Serum CXCL10 levels significantly decreased in GD patients 6 months after 131I treatment, whereas they remained within normal limits in TNG patients after restoration of euthyroidism by 131I. CONCLUSIONS: In conclusion, our results demonstrate that high serum CXCL10 levels are associated with the hyperthyroid phase in GD but not TNG, providing further evidence for a minimal role of hyperthyroidism per se in determining high CXCL10 levels and showing a strong association with the autoimmune process. The reduction of CXCL10 levels after 131I treatment in GD only shows that the thyroid gland itself is the main source of circulating CXCL10.
Alessandro Antonelli - One of the best experts on this subject based on the ideXlab platform.
-
Chemokine c x c motif ligand cxcl 10 in autoimmune diseases
Autoimmunity Reviews, 2014Co-Authors: Alessandro Antonelli, Ele Ferrannini, Silvia Martina Ferrari, Dilia Giuggioli, Clodoveo Ferri, Poupak FallahiAbstract:(C–X–C motif) ligand (CXCL)10 (CXCL10) belongs to the ELR− CXC subfamily Chemokine. CXCL10 exerts its function through binding to Chemokine (C–X–C motif) receptor 3 (CXCR3), a seven trans-membrane receptor coupled to G proteins. CXCL10 and its receptor, CXCR3, appear to contribute to the pathogenesis of many autoimmune diseases, organ specific (such as type 1 diabetes, autoimmune thyroiditis, Graves' disease and ophthalmopathy), or systemic (such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, mixed cryoglobulinemia, Sjogren syndrome, or systemic sclerosis). The secretion of CXCL10 by cluster of differentiation (CD)4 +, CD8 +, natural killer (NK) and NK-T cells is dependent on interferon (IFN)-γ, which is itself mediated by the interleukin-12 cytokine family. Under the influence of IFN-γ, CXCL10 is secreted by several cell types including endothelial cells, fibroblasts, keratinocytes, thyrocytes, preadipocytes, etc. Determination of high level of CXCL10 in peripheral fluids is therefore a marker of host immune response, especially T helper (Th)1 orientated T-cells. In tissues, recruited Th1 lymphocytes may be responsible for enhanced IFN-γ and tumor necrosis factor-α production, which in turn stimulates CXCL10 secretion from a variety of cells, therefore creating an amplification feedback loop, and perpetuating the autoimmune process. Further studies are needed to investigate interactions between Chemokines and cytokines in the pathogenesis of autoimmune diseases and to evaluate whether CXCL10 is a novel therapeutic target in various autoimmune diseases.
-
monokine induced by interferon γ ifnγ cxcl9 and ifnγ inducible t cell α chemoattractant cxcl11 involvement in graves disease and ophthalmopathy modulation by peroxisome proliferator activated receptor γ agonists
The Journal of Clinical Endocrinology and Metabolism, 2009Co-Authors: Alessandro Antonelli, Poupak Fallahi, Stefano Sellari Franceschini, Silvia Martina Ferrari, Silvia Frascerra, Eleonora Santini, Ele FerranniniAbstract:Context: CXC α-Chemokine CXCL10/IP-10 plays an important role in the initial phases of Graves’ ophthalmopathy (GO). Human thyrocytes, orbital fibroblasts, and preadipocytes are stimulated to produce CXCL10 when treated with interferon γ (IFNγ) and TNFα. Peroxisome proliferator-activated receptor-γ (PPARγ) activation plays an inhibitory role in this process. Objective: Until now, no data are present in literature about the involvement of CXCL9 and CXCL11 in Graves’ disease and GO, or of PPARγ activators’ effect on these Chemokines. Methods: It has been studied how IFNγ and TNFα stimulation and PPARγ activation affect CXCL9 and CXCL11 secretion in primary cultures of thyrocytes, orbital fibroblasts, and preadipocytes. Results: In primary cultures of thyrocytes, retrobulbar fibroblasts, and retrobulbar preadipocytes obtained from GO patients, CXCL9 and CXCL11 production was absent under basal conditions; CXCL9 and CXCL11 secretion was not induced by TNFα alone, whereas it was dose dependently stimulated trea...
-
monokine induced by interferon gamma ifngamma cxcl9 and ifngamma inducible t cell alpha chemoattractant cxcl11 involvement in graves disease and ophthalmopathy modulation by peroxisome proliferator activated receptor gamma agonists
The Journal of Clinical Endocrinology and Metabolism, 2009Co-Authors: Alessandro Antonelli, Poupak Fallahi, Stefano Sellari Franceschini, Silvia Martina Ferrari, Silvia Frascerra, Eleonora Santini, Ele FerranniniAbstract:Context: CXC α-Chemokine CXCL10/IP-10 plays an important role in the initial phases of Graves’ ophthalmopathy (GO). Human thyrocytes, orbital fibroblasts, and preadipocytes are stimulated to produce CXCL10 when treated with interferon γ (IFNγ) and TNFα. Peroxisome proliferator-activated receptor-γ (PPARγ) activation plays an inhibitory role in this process. Objective: Until now, no data are present in literature about the involvement of CXCL9 and CXCL11 in Graves’ disease and GO, or of PPARγ activators’ effect on these Chemokines. Methods: It has been studied how IFNγ and TNFα stimulation and PPARγ activation affect CXCL9 and CXCL11 secretion in primary cultures of thyrocytes, orbital fibroblasts, and preadipocytes. Results: In primary cultures of thyrocytes, retrobulbar fibroblasts, and retrobulbar preadipocytes obtained from GO patients, CXCL9 and CXCL11 production was absent under basal conditions; CXCL9 and CXCL11 secretion was not induced by TNFα alone, whereas it was dose dependently stimulated trea...
-
α Chemokine CXCL10 and β Chemokine ccl2 serum levels in patients with hepatitis c associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis
Metabolism-clinical and Experimental, 2008Co-Authors: Alessandro Antonelli, Poupak Fallahi, Silvia Martina Ferrari, Silvia Frascerra, Clodoveo Ferri, Angelo Carpi, Andrea Nicolini, Ele FerranniniAbstract:Chemokines have been identified to play an important role in endocrine autoimmune disease and hepatitis C chronic infection. To our knowledge, no study has evaluated serum levels of CXCL10 and CCL2 in patients with “mixed cryoglobulinemia and hepatitis C virus chronic infection” (MC) in the presence or absence of autoimmune thyroiditis (AT). Serum CXCL10 and CCL2 were assayed in 60 patients with MC, in 45 patients with “MC with AT” (MC + AT), and in controls (60 without [control 1] and 45 with AT [control 2]). CXCL10 was significantly higher (1) in control 2 than in control 1 (P mean + SD control 1; >167 pg/mL) was present in 7% control 1, 21% control 2, 49% MC, and 78% MC + AT (P mean + SD control 1; >730 pg/mL) was present in 2% control 1, 1% control 2, 18% MC, and 21% MC + AT (P < .0001). The study demonstrates high CXCL10 and CCL2 serum levels in patients with MC; CXCL10 in MC + AT is significantly higher than that in MC. Future studies in larger series will be needed to evaluate the potential usefulness of serum CXCL10 and CCL2 determination as a prognostic marker in the follow-up of MC patients, also in relation to the presence of AT.
-
iodine 131 given for therapeutic purposes modulates differently interferon γ inducible α Chemokine CXCL10 serum levels in patients with active graves disease or toxic nodular goiter
The Journal of Clinical Endocrinology and Metabolism, 2007Co-Authors: Alessandro Antonelli, Poupak Fallahi, Paola Romagnani, Mario Serio, Mariano Grosso, Giuseppe Boni, Silvia Martina Ferrari, Giuliano Mariani, M Rotondi, Ele FerranniniAbstract:CONTEXT: The mechanism of activation of the immune system after iodine-131 (131I) treatment of hyperthyroidism is still not fully clarified. Serum levels of CXCL10, a prototype of the CXC family of Chemokines, are increased in several endocrine autoimmune conditions, and this Chemokine plays a role at least in the initial phases of thyroid autoimmune disease and in Graves' disease (GD). OBJECTIVE, DESIGN, AND PATIENTS: The aim of the present study was to measure the serum CXCL10 levels in 20 patients with GD and 10 patients with toxic nodular goiter (TNG) before and 6 months after 131I treatment, when patients had achieved euthyroidism. Forty healthy subjects and 40 patients with autoimmune thyroiditis served as control groups. RESULTS: Before 131I, mean CXCL10 was significantly higher in patients with GD and thyroiditis than controls or those with TNG. Serum CXCL10 levels significantly decreased in GD patients 6 months after 131I treatment, whereas they remained within normal limits in TNG patients after restoration of euthyroidism by 131I. CONCLUSIONS: In conclusion, our results demonstrate that high serum CXCL10 levels are associated with the hyperthyroid phase in GD but not TNG, providing further evidence for a minimal role of hyperthyroidism per se in determining high CXCL10 levels and showing a strong association with the autoimmune process. The reduction of CXCL10 levels after 131I treatment in GD only shows that the thyroid gland itself is the main source of circulating CXCL10.
Poupak Fallahi - One of the best experts on this subject based on the ideXlab platform.
-
Chemokine c x c motif ligand cxcl 10 in autoimmune diseases
Autoimmunity Reviews, 2014Co-Authors: Alessandro Antonelli, Ele Ferrannini, Silvia Martina Ferrari, Dilia Giuggioli, Clodoveo Ferri, Poupak FallahiAbstract:(C–X–C motif) ligand (CXCL)10 (CXCL10) belongs to the ELR− CXC subfamily Chemokine. CXCL10 exerts its function through binding to Chemokine (C–X–C motif) receptor 3 (CXCR3), a seven trans-membrane receptor coupled to G proteins. CXCL10 and its receptor, CXCR3, appear to contribute to the pathogenesis of many autoimmune diseases, organ specific (such as type 1 diabetes, autoimmune thyroiditis, Graves' disease and ophthalmopathy), or systemic (such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, mixed cryoglobulinemia, Sjogren syndrome, or systemic sclerosis). The secretion of CXCL10 by cluster of differentiation (CD)4 +, CD8 +, natural killer (NK) and NK-T cells is dependent on interferon (IFN)-γ, which is itself mediated by the interleukin-12 cytokine family. Under the influence of IFN-γ, CXCL10 is secreted by several cell types including endothelial cells, fibroblasts, keratinocytes, thyrocytes, preadipocytes, etc. Determination of high level of CXCL10 in peripheral fluids is therefore a marker of host immune response, especially T helper (Th)1 orientated T-cells. In tissues, recruited Th1 lymphocytes may be responsible for enhanced IFN-γ and tumor necrosis factor-α production, which in turn stimulates CXCL10 secretion from a variety of cells, therefore creating an amplification feedback loop, and perpetuating the autoimmune process. Further studies are needed to investigate interactions between Chemokines and cytokines in the pathogenesis of autoimmune diseases and to evaluate whether CXCL10 is a novel therapeutic target in various autoimmune diseases.
-
monokine induced by interferon γ ifnγ cxcl9 and ifnγ inducible t cell α chemoattractant cxcl11 involvement in graves disease and ophthalmopathy modulation by peroxisome proliferator activated receptor γ agonists
The Journal of Clinical Endocrinology and Metabolism, 2009Co-Authors: Alessandro Antonelli, Poupak Fallahi, Stefano Sellari Franceschini, Silvia Martina Ferrari, Silvia Frascerra, Eleonora Santini, Ele FerranniniAbstract:Context: CXC α-Chemokine CXCL10/IP-10 plays an important role in the initial phases of Graves’ ophthalmopathy (GO). Human thyrocytes, orbital fibroblasts, and preadipocytes are stimulated to produce CXCL10 when treated with interferon γ (IFNγ) and TNFα. Peroxisome proliferator-activated receptor-γ (PPARγ) activation plays an inhibitory role in this process. Objective: Until now, no data are present in literature about the involvement of CXCL9 and CXCL11 in Graves’ disease and GO, or of PPARγ activators’ effect on these Chemokines. Methods: It has been studied how IFNγ and TNFα stimulation and PPARγ activation affect CXCL9 and CXCL11 secretion in primary cultures of thyrocytes, orbital fibroblasts, and preadipocytes. Results: In primary cultures of thyrocytes, retrobulbar fibroblasts, and retrobulbar preadipocytes obtained from GO patients, CXCL9 and CXCL11 production was absent under basal conditions; CXCL9 and CXCL11 secretion was not induced by TNFα alone, whereas it was dose dependently stimulated trea...
-
monokine induced by interferon gamma ifngamma cxcl9 and ifngamma inducible t cell alpha chemoattractant cxcl11 involvement in graves disease and ophthalmopathy modulation by peroxisome proliferator activated receptor gamma agonists
The Journal of Clinical Endocrinology and Metabolism, 2009Co-Authors: Alessandro Antonelli, Poupak Fallahi, Stefano Sellari Franceschini, Silvia Martina Ferrari, Silvia Frascerra, Eleonora Santini, Ele FerranniniAbstract:Context: CXC α-Chemokine CXCL10/IP-10 plays an important role in the initial phases of Graves’ ophthalmopathy (GO). Human thyrocytes, orbital fibroblasts, and preadipocytes are stimulated to produce CXCL10 when treated with interferon γ (IFNγ) and TNFα. Peroxisome proliferator-activated receptor-γ (PPARγ) activation plays an inhibitory role in this process. Objective: Until now, no data are present in literature about the involvement of CXCL9 and CXCL11 in Graves’ disease and GO, or of PPARγ activators’ effect on these Chemokines. Methods: It has been studied how IFNγ and TNFα stimulation and PPARγ activation affect CXCL9 and CXCL11 secretion in primary cultures of thyrocytes, orbital fibroblasts, and preadipocytes. Results: In primary cultures of thyrocytes, retrobulbar fibroblasts, and retrobulbar preadipocytes obtained from GO patients, CXCL9 and CXCL11 production was absent under basal conditions; CXCL9 and CXCL11 secretion was not induced by TNFα alone, whereas it was dose dependently stimulated trea...
-
α Chemokine CXCL10 and β Chemokine ccl2 serum levels in patients with hepatitis c associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis
Metabolism-clinical and Experimental, 2008Co-Authors: Alessandro Antonelli, Poupak Fallahi, Silvia Martina Ferrari, Silvia Frascerra, Clodoveo Ferri, Angelo Carpi, Andrea Nicolini, Ele FerranniniAbstract:Chemokines have been identified to play an important role in endocrine autoimmune disease and hepatitis C chronic infection. To our knowledge, no study has evaluated serum levels of CXCL10 and CCL2 in patients with “mixed cryoglobulinemia and hepatitis C virus chronic infection” (MC) in the presence or absence of autoimmune thyroiditis (AT). Serum CXCL10 and CCL2 were assayed in 60 patients with MC, in 45 patients with “MC with AT” (MC + AT), and in controls (60 without [control 1] and 45 with AT [control 2]). CXCL10 was significantly higher (1) in control 2 than in control 1 (P mean + SD control 1; >167 pg/mL) was present in 7% control 1, 21% control 2, 49% MC, and 78% MC + AT (P mean + SD control 1; >730 pg/mL) was present in 2% control 1, 1% control 2, 18% MC, and 21% MC + AT (P < .0001). The study demonstrates high CXCL10 and CCL2 serum levels in patients with MC; CXCL10 in MC + AT is significantly higher than that in MC. Future studies in larger series will be needed to evaluate the potential usefulness of serum CXCL10 and CCL2 determination as a prognostic marker in the follow-up of MC patients, also in relation to the presence of AT.
-
iodine 131 given for therapeutic purposes modulates differently interferon γ inducible α Chemokine CXCL10 serum levels in patients with active graves disease or toxic nodular goiter
The Journal of Clinical Endocrinology and Metabolism, 2007Co-Authors: Alessandro Antonelli, Poupak Fallahi, Paola Romagnani, Mario Serio, Mariano Grosso, Giuseppe Boni, Silvia Martina Ferrari, Giuliano Mariani, M Rotondi, Ele FerranniniAbstract:CONTEXT: The mechanism of activation of the immune system after iodine-131 (131I) treatment of hyperthyroidism is still not fully clarified. Serum levels of CXCL10, a prototype of the CXC family of Chemokines, are increased in several endocrine autoimmune conditions, and this Chemokine plays a role at least in the initial phases of thyroid autoimmune disease and in Graves' disease (GD). OBJECTIVE, DESIGN, AND PATIENTS: The aim of the present study was to measure the serum CXCL10 levels in 20 patients with GD and 10 patients with toxic nodular goiter (TNG) before and 6 months after 131I treatment, when patients had achieved euthyroidism. Forty healthy subjects and 40 patients with autoimmune thyroiditis served as control groups. RESULTS: Before 131I, mean CXCL10 was significantly higher in patients with GD and thyroiditis than controls or those with TNG. Serum CXCL10 levels significantly decreased in GD patients 6 months after 131I treatment, whereas they remained within normal limits in TNG patients after restoration of euthyroidism by 131I. CONCLUSIONS: In conclusion, our results demonstrate that high serum CXCL10 levels are associated with the hyperthyroid phase in GD but not TNG, providing further evidence for a minimal role of hyperthyroidism per se in determining high CXCL10 levels and showing a strong association with the autoimmune process. The reduction of CXCL10 levels after 131I treatment in GD only shows that the thyroid gland itself is the main source of circulating CXCL10.
Mario Serio - One of the best experts on this subject based on the ideXlab platform.
-
iodine 131 given for therapeutic purposes modulates differently interferon γ inducible α Chemokine CXCL10 serum levels in patients with active graves disease or toxic nodular goiter
The Journal of Clinical Endocrinology and Metabolism, 2007Co-Authors: Alessandro Antonelli, Poupak Fallahi, Paola Romagnani, Mario Serio, Mariano Grosso, Giuseppe Boni, Silvia Martina Ferrari, Giuliano Mariani, M Rotondi, Ele FerranniniAbstract:CONTEXT: The mechanism of activation of the immune system after iodine-131 (131I) treatment of hyperthyroidism is still not fully clarified. Serum levels of CXCL10, a prototype of the CXC family of Chemokines, are increased in several endocrine autoimmune conditions, and this Chemokine plays a role at least in the initial phases of thyroid autoimmune disease and in Graves' disease (GD). OBJECTIVE, DESIGN, AND PATIENTS: The aim of the present study was to measure the serum CXCL10 levels in 20 patients with GD and 10 patients with toxic nodular goiter (TNG) before and 6 months after 131I treatment, when patients had achieved euthyroidism. Forty healthy subjects and 40 patients with autoimmune thyroiditis served as control groups. RESULTS: Before 131I, mean CXCL10 was significantly higher in patients with GD and thyroiditis than controls or those with TNG. Serum CXCL10 levels significantly decreased in GD patients 6 months after 131I treatment, whereas they remained within normal limits in TNG patients after restoration of euthyroidism by 131I. CONCLUSIONS: In conclusion, our results demonstrate that high serum CXCL10 levels are associated with the hyperthyroid phase in GD but not TNG, providing further evidence for a minimal role of hyperthyroidism per se in determining high CXCL10 levels and showing a strong association with the autoimmune process. The reduction of CXCL10 levels after 131I treatment in GD only shows that the thyroid gland itself is the main source of circulating CXCL10.
-
Iodine-131 Given for Therapeutic Purposes Modulates Differently Interferon-γ-Inducible α-Chemokine CXCL10 Serum Levels in Patients with Active Graves’ Disease or Toxic Nodular Goiter
The Journal of clinical endocrinology and metabolism, 2007Co-Authors: Alessandro Antonelli, Poupak Fallahi, Paola Romagnani, Mario Rotondi, Mario Serio, Mariano Grosso, Giuseppe Boni, Silvia Martina Ferrari, Giuliano Mariani, Ele FerranniniAbstract:Context: The mechanism of activation of the immune system after iodine-131 (131I) treatment of hyperthyroidism is still not fully clarified. Serum levels of CXCL10, a prototype of the CXC family of Chemokines, are increased in several endocrine autoimmune conditions, and this Chemokine plays a role at least in the initial phases of thyroid autoimmune disease and in Graves’ disease (GD). Objective, Design, and Patients: The aim of the present study was to measure the serum CXCL10 levels in 20 patients with GD and 10 patients with toxic nodular goiter (TNG) before and 6 months after 131I treatment, when patients had achieved euthyroidism. Forty healthy subjects and 40 patients with autoimmune thyroiditis served as control groups. Results: Before 131I, mean CXCL10 was significantly higher in patients with GD and thyroiditis than controls or those with TNG. Serum CXCL10 levels significantly decreased in GD patients 6 months after 131I treatment, whereas they remained within normal limits in TNG patients after...
-
serum levels of the interferon γ inducible α Chemokine CXCL10 in patients with active graves disease and modulation by methimazole therapy and thyroidectomy
British Journal of Surgery, 2006Co-Authors: Alessandro Antonelli, Poupak Fallahi, Mario Rotondi, Mario Serio, S M Ferrari, Paolo MiccoliAbstract:Background: The interferon-γ-inducible Chemokine CXCL10 is highly expressed in infiltrating inflammatory cells, and in thyrocytes in patients with Graves' disease. The aim of this study was to measure serum levels of CXCL10 in relation to thyroid function and treatment. Methods: Serum levels of CXCL10 were measured in 22 patients with Graves' disease when hyperthyroid, when euthyroid under methimazole therapy, and 3 days after near-total thyroidectomy. They were compared with levels in three groups of age- and sex-matched controls: 44 subjects with no thyroid disorder, 44 patients with euthyroid autoimmune thyroiditis and 20 with toxic nodular goitre. Results: Basal serum levels of CXCL10 in patients with Graves' disease were higher than levels in patients with toxic nodular goitre or no thyroid disorder, and similar to levels in patients with autoimmune thyroiditis (mean(s.d.) 167(121), 100(24), 78(46) and 142(107) pg/ml respectively; P < 0·010). Among patients with Graves' disease, serum levels of CXCL10 were significantly higher in those aged over 50 years (P = 0·010), with a hypoechoic pattern at thyroid ultrasonography (P < 0·001) or with hypervascularity (P = 0·001). CXCL10 levels in patients with Graves' disease decreased significantly when euthyroidism was achieved by methimazole therapy (P < 0·010), and a further decrease was observed after thyroidectomy (P < 0·010). Conclusion: Serum levels of CXCL10 are higher in newly diagnosed hyperthyroid patients with Graves' disease than in those with toxic nodular goitre, and decrease when euthyroidism is achieved with antithyroid therapy. This high level may be related to the active inflammatory phase of Graves' disease. A further reduction of CXCL10 levels after thyroidectomy indicates that it is produced mainly in the thyroid in patients with autoimmune thyroid disease. Copyright © 2006 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
-
increase of cxc Chemokine CXCL10 and cc Chemokine ccl2 serum levels in normal ageing
Cytokine, 2006Co-Authors: Alessandro Antonelli, Poupak Fallahi, Paola Romagnani, Mario Rotondi, Aldo Paolicchi, Mario Serio, Silvia Martina Ferrari, Ele FerranniniAbstract:Abstract No study has evaluated contemporaneously serum CXC and CC Chemokines changes in normal ageing. Serum levels of CXCL10 (sCXCL10) (CXC) and CCL2 (sCCL2) (CC) prototype Chemokines have been measured in 164 healthy subjects, from 10 to 79 years of age (82 males/82 females). By simple regression analysis, sCXCL10 and sCCL2 were significantly related with increasing age (r = 0.32, p 150 pg/ml) were not significantly associated with those with high sCCL2 levels (>559 pg/ml). This study, performed in healthy subjects on an age gradient, demonstrates an increase of sCXCL10 and sCCL2 with advancing age; the differential increase of sCXCL10 or sCCL2 may reflect a general shift towards Th1 or Th2 cytokines pattern, respectively.
-
interferon γ inducible α Chemokine CXCL10 involvement in graves ophthalmopathy modulation by peroxisome proliferator activated receptor γ agonists
The Journal of Clinical Endocrinology and Metabolism, 2006Co-Authors: Alessandro Antonelli, Poupak Fallahi, Paola Romagnani, Mario Rotondi, Silvia Ferrari, Mario Serio, Stefano Sellari Franceschini, Ele FerranniniAbstract:Context: CXC α-Chemokine CXCL10/inducing protein-10 play an important role in the initial phases of autoimmune thyroid disorders. Human thyrocytes in primary culture produce large amounts of CXCL10 when stimulated by interferon-γ (IFNγ) and TNFα. Objective: Serum CXCL10 levels (sCXCL10) were measured in patients with active or inactive Graves’ ophthalmopathy (GO). The effects of IFNγ and TNFα stimulation and peroxisome proliferator-activated receptor-γ (PPARγ) activation on CXCL10 secretion in primary cultures of thyrocytes, orbital fibroblasts, and preadipocytes were tested. Patients: Sixty consecutive patients with Graves’ disease, 60 age- and sex-matched patients with GO, and 60 controls were studied. Results: sCXCL10 was higher (P < 0.0001) in Graves’ disease (120 ± 83 pg/ml; n = 60) and GO (122 ± 71; n = 60) patients than in age- and sex-matched euthyroid controls (72 ± 32; n = 60). Among GO patients, sCXCL10 levels were significantly higher in those (n = 14) with active disease (171 ± 197) than in t...
Mario Rotondi - One of the best experts on this subject based on the ideXlab platform.
-
covid 19 pulmonary and olfactory dysfunctions is the Chemokine CXCL10 the common denominator
The Neuroscientist, 2020Co-Authors: Antonio Oliviero, Fernando De Castro, Francesca Coperchini, Luca Chiovato, Mario RotondiAbstract:COVID-19 is an ongoing viral pandemic that emerged from East Asia and quickly spread to the rest of the world. SARS-CoV-2 is the virus causing COVID-19. Acute respiratory distress syndrome (ARDS) is definitely one of the main clinically relevant consequences in patients with COVID-19. Starting from the earliest reports of the COVID-19 pandemic, two peculiar neurological manifestations (namely, hyposmia/anosmia and dysgeusia) were reported in a relevant proportion of patients infected by SARS-CoV-2. At present, the physiopathologic mechanisms accounting for the onset of these symptoms are not yet clarified. CXCL10 is a pro-inflammatory Chemokine with a well-established role in the COVID-19-related cytokine storm and in subsequent development of ARDS. CXCL10 is also known to be involved in coronavirus-induced demyelination. On these bases, a role for CXCL10 as the common denominator between pulmonary and olfactory dysfunctions could be envisaged. The aim of the present report will be to hypothesize a role for CXCL10 in COVID-19 olfactory dysfunctions. Previous evidences supporting our hypothesis, with special emphasis to the role of CXCL10 in coronavirus-induced demyelination, the anatomical and physiological peculiarity of the olfactory system, and the available data supporting their link during COVID-19 infections, will be overviewed.
-
Iodine-131 Given for Therapeutic Purposes Modulates Differently Interferon-γ-Inducible α-Chemokine CXCL10 Serum Levels in Patients with Active Graves’ Disease or Toxic Nodular Goiter
The Journal of clinical endocrinology and metabolism, 2007Co-Authors: Alessandro Antonelli, Poupak Fallahi, Paola Romagnani, Mario Rotondi, Mario Serio, Mariano Grosso, Giuseppe Boni, Silvia Martina Ferrari, Giuliano Mariani, Ele FerranniniAbstract:Context: The mechanism of activation of the immune system after iodine-131 (131I) treatment of hyperthyroidism is still not fully clarified. Serum levels of CXCL10, a prototype of the CXC family of Chemokines, are increased in several endocrine autoimmune conditions, and this Chemokine plays a role at least in the initial phases of thyroid autoimmune disease and in Graves’ disease (GD). Objective, Design, and Patients: The aim of the present study was to measure the serum CXCL10 levels in 20 patients with GD and 10 patients with toxic nodular goiter (TNG) before and 6 months after 131I treatment, when patients had achieved euthyroidism. Forty healthy subjects and 40 patients with autoimmune thyroiditis served as control groups. Results: Before 131I, mean CXCL10 was significantly higher in patients with GD and thyroiditis than controls or those with TNG. Serum CXCL10 levels significantly decreased in GD patients 6 months after 131I treatment, whereas they remained within normal limits in TNG patients after...
-
serum levels of the interferon γ inducible α Chemokine CXCL10 in patients with active graves disease and modulation by methimazole therapy and thyroidectomy
British Journal of Surgery, 2006Co-Authors: Alessandro Antonelli, Poupak Fallahi, Mario Rotondi, Mario Serio, S M Ferrari, Paolo MiccoliAbstract:Background: The interferon-γ-inducible Chemokine CXCL10 is highly expressed in infiltrating inflammatory cells, and in thyrocytes in patients with Graves' disease. The aim of this study was to measure serum levels of CXCL10 in relation to thyroid function and treatment. Methods: Serum levels of CXCL10 were measured in 22 patients with Graves' disease when hyperthyroid, when euthyroid under methimazole therapy, and 3 days after near-total thyroidectomy. They were compared with levels in three groups of age- and sex-matched controls: 44 subjects with no thyroid disorder, 44 patients with euthyroid autoimmune thyroiditis and 20 with toxic nodular goitre. Results: Basal serum levels of CXCL10 in patients with Graves' disease were higher than levels in patients with toxic nodular goitre or no thyroid disorder, and similar to levels in patients with autoimmune thyroiditis (mean(s.d.) 167(121), 100(24), 78(46) and 142(107) pg/ml respectively; P < 0·010). Among patients with Graves' disease, serum levels of CXCL10 were significantly higher in those aged over 50 years (P = 0·010), with a hypoechoic pattern at thyroid ultrasonography (P < 0·001) or with hypervascularity (P = 0·001). CXCL10 levels in patients with Graves' disease decreased significantly when euthyroidism was achieved by methimazole therapy (P < 0·010), and a further decrease was observed after thyroidectomy (P < 0·010). Conclusion: Serum levels of CXCL10 are higher in newly diagnosed hyperthyroid patients with Graves' disease than in those with toxic nodular goitre, and decrease when euthyroidism is achieved with antithyroid therapy. This high level may be related to the active inflammatory phase of Graves' disease. A further reduction of CXCL10 levels after thyroidectomy indicates that it is produced mainly in the thyroid in patients with autoimmune thyroid disease. Copyright © 2006 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
-
increase of cxc Chemokine CXCL10 and cc Chemokine ccl2 serum levels in normal ageing
Cytokine, 2006Co-Authors: Alessandro Antonelli, Poupak Fallahi, Paola Romagnani, Mario Rotondi, Aldo Paolicchi, Mario Serio, Silvia Martina Ferrari, Ele FerranniniAbstract:Abstract No study has evaluated contemporaneously serum CXC and CC Chemokines changes in normal ageing. Serum levels of CXCL10 (sCXCL10) (CXC) and CCL2 (sCCL2) (CC) prototype Chemokines have been measured in 164 healthy subjects, from 10 to 79 years of age (82 males/82 females). By simple regression analysis, sCXCL10 and sCCL2 were significantly related with increasing age (r = 0.32, p 150 pg/ml) were not significantly associated with those with high sCCL2 levels (>559 pg/ml). This study, performed in healthy subjects on an age gradient, demonstrates an increase of sCXCL10 and sCCL2 with advancing age; the differential increase of sCXCL10 or sCCL2 may reflect a general shift towards Th1 or Th2 cytokines pattern, respectively.
-
interferon γ inducible α Chemokine CXCL10 involvement in graves ophthalmopathy modulation by peroxisome proliferator activated receptor γ agonists
The Journal of Clinical Endocrinology and Metabolism, 2006Co-Authors: Alessandro Antonelli, Poupak Fallahi, Paola Romagnani, Mario Rotondi, Silvia Ferrari, Mario Serio, Stefano Sellari Franceschini, Ele FerranniniAbstract:Context: CXC α-Chemokine CXCL10/inducing protein-10 play an important role in the initial phases of autoimmune thyroid disorders. Human thyrocytes in primary culture produce large amounts of CXCL10 when stimulated by interferon-γ (IFNγ) and TNFα. Objective: Serum CXCL10 levels (sCXCL10) were measured in patients with active or inactive Graves’ ophthalmopathy (GO). The effects of IFNγ and TNFα stimulation and peroxisome proliferator-activated receptor-γ (PPARγ) activation on CXCL10 secretion in primary cultures of thyrocytes, orbital fibroblasts, and preadipocytes were tested. Patients: Sixty consecutive patients with Graves’ disease, 60 age- and sex-matched patients with GO, and 60 controls were studied. Results: sCXCL10 was higher (P < 0.0001) in Graves’ disease (120 ± 83 pg/ml; n = 60) and GO (122 ± 71; n = 60) patients than in age- and sex-matched euthyroid controls (72 ± 32; n = 60). Among GO patients, sCXCL10 levels were significantly higher in those (n = 14) with active disease (171 ± 197) than in t...